The tumor suppressor protein p16 INK4a (p16) is a well-established hallmark of aging that induces cellular senescence in response to stress. Previous studies have focused primarily on p16 regulation at the transcriptional level; comparatively little is known about the protein's intracellular localization and degradation. The autophagy-lysosomal pathway has been implicated in the subcellular trafficking and turnover of various stressresponse proteins, but it is unclear whether p16 is involved in these pathways. Here, we investigate the role of autophagy, vesicular trafficking, and lysosomal degradation on p16 expression and localization in human epithelial cells. Time-lapse fluorescence microscopy using an endogenous p16-mCherry reporter revealed that autophagy induced by genotoxic stress stimulates rapid p16 recruitment to acidic cytoplasmic vesicles. When vesicular acidification was inhibited by NH4Cl, nuclear p16 levels increased. Single-cell imaging revealed that p16 localizes to lysosomes upon stress, implicating the autophagy pathway as a regulator of p16 localization. Blocking autophagy with bafilomycin, chloroquine, or NH4Cl resulted in elevated p16 protein levels without increased transcription. Increased p16 coincided with accumulation of autophagosome chaperone p62/SQSTM1 (p62) and decreased levels of phosphorylated-Rb. Furthermore, chloroquine caused p16 aggregation within stalled vesicles containing autophagosome marker LC3, demonstrating that p16 is transported and degraded by the autophagylysosomal pathway. Knockdown of p62 resulted in delocalization of p16 aggregates to autophagosomes, suggesting that p16 is targeted to these vesicles by p62. Taken together, these results implicate the autophagy pathway as a novel regulator of p16 degradation and localization, which could play a role in the etiology of cancer and agerelated diseases.
Introduction
The tumor suppressor protein p16 INK4a (CDKN2A, p16) is a member of the INK4 family of cyclin-dependent kinase inhibitors, which play a critical role in cell cycle regulation.
Expression of p16 prevents cellular proliferation by binding and inhibiting cyclindependent kinases 4 and 6 (CDK4/6). In response to oncogene expression and prolonged DNA damage, p16 induces cellular senescence (permanent cell cycle arrest) [1] . As an organism ages, p16 accumulates in tissues, which triggers cellular senescence.
Clearance of p16 expressing senescent cells has been linked to an increase in lifespan and a decrease in tumorigenesis [2] . The correlation between p16 expression and aging is so strong that p16 is commonly used as a biomarker for aging [3] . While the mechanisms regulating transcription of p16 have been well described, studies about the localization and degradation of the p16 protein are lacking.
p16 is expressed in both the nucleus and the cytoplasm [4] ; [5] . Whereas the role of p16 in the nucleus as an inhibitor of CDK4/6 is well understood, its subcellular localization and function in the cytoplasm remains mysterious. Immunohistological studies of patient tumors have suggested p16 localization as a possible indicator of clinical prognosis. However, many of these studies present contradictory claims that indicate a complex role for p16 localization in tumor progression. For example, cytoplasmic p16 has been reported to be a predictor of poor prognosis in patients with astrocytic brain tumors [6] .
However, cytoplasmic p16 has also been reported as correlating with the absence of metastasis in other cancer types, such as melanoma [7] . Commonly used chemotherapeutic drugs such as etoposide and doxorubicin can increase p16 protein levels and induce senescence [8] , but whether and to what extent these agents affect p16 localization has not been fully explored. Interestingly, p16 does not have a known nuclear localization signal (NLS) or a nuclear export signal (NES) [9] , suggesting that an indirect mechanism of intracellular transport is responsible for shuttling p16 between different cellular compartments [10] .
One potential mechanism for regulation of p16 localization is vesicular trafficking via the lysosomal endomembrane system. Lysosomes are cytoplasmic organelles involved in autophagy-mediated protein degradation. Like p16, lysosomes are involved in senescence-associated signaling pathways, and lysosome dysfunction has been linked to a myriad of age-related pathologies and a decrease in lifespan [11] ; [12] ; [13] . Similarly, lysosomes have also been targeted for lifespan extension therapies, such as intervention with rapamycin and spermidine [11] . Recent studies have expanded beyond protein degradation and explored the role of lysosomes in subcellular localization of stressresponse proteins and the regulation of cell fate. For example, the mechanistic target of rapamycin (mTOR) was found to not only be recruited and degraded by lysosomes, but also play an important role in lysosome formation and regulation of the entire autophagy pathway [14] . Given the correlation of both autophagy and p16 expression with cellular aging and senescence, an intriguing hypothesis is that p16 localization, degradation, and regulation may be mediated by lysosomes and other members of this pathway. Previous experiments have shown that p16 can be degraded by the proteasome [15] ; however, no literature exists to support whether regulation can also occur through other known degradation mechanisms such as the autophagy/lysosomal pathway. Figure 1 , the autophagy pathway consists of several sequential steps, beginning with stimulation by nutrient starvation or stress, followed by interaction between several endomembrane vesicles, and ending with the lysosomal degradation of proteins.
As shown in
Autophagy can be both selective and non-selective. For selective autophagy, ubiquitinated proteins or protein aggregates can be targeted for lysosomal degradation by ubiquitin-binding protein p62 (also known as sequestosome 1; SQSTM1). Although p16 does not contain a lysine residue, N-terminal ubiquitination of p16 has been reported [15] . p62-bound proteins are enveloped by autophagosomes, which are identifiable by autophagosome marker Membrane-bound microtubule-associated protein 1A/1B-light chain 3 (LC3). Autophagosomes then fuse to lysosomes (identifiable by Lysosomalassociated membrane protein 1 LAMP-1) containing low-pH dependent hydrolases, forming autolysosomes. The pH gradient of these vesicles lowers throughout this process, provoking the degradation of proteins within the autolysosome, including p62 and LC3. Autophagic flux, or the rate at which proteins are degraded by this pathway, can change in response to cellular stress and nutrient availability. Changes in autophagic flux can rapidly affect the localization and expression dynamics of proteins involved in this pathway [16] . Accordingly, researchers studying autophagy often employ inhibitors to capture proteins in transit within this pathway. Examples of well-characterized autophagy inhibitors include bafilomycin A1, chloroquine, and ammonium chloride, which act by preventing the fusion of autophagosomes and lysosomes, and by raising vesicular pH, which prevents hydrolase activity [17] .
In this study, we investigated the relationship between p16 and the autophagy/lysosomal pathway in human cells. By engineering a live-cell reporter for p16, we found that activation of autophagy caused p16 to accumulate in acidic cytoplasmic vesicles that stained positive for the lysosome marker LAMP-1. Neutralizing lysosomes led to increased p16 levels and preferential accumulation of nuclear p16. Chemical inhibition of autophagy led to increases in p16 protein as well as the autophagosome chaperone p62. Depletion of p62 abolished the ability of p16 to colocalize with autophagosomes. Taken together, these results show that p16 is localized and degraded through the autophagy/lysosomal pathway, implicating the autophagy pathway as a potential regulator of p16-induced senescence.
Results

Localization dynamics of p16 in response to autophagy and genotoxic stress
Autophagy is a highly dynamic process involving rapid protein transport and turnover known as autophagic flux. As a consequence, many autophagy markers and proteins targeted for degradation are difficult to measure [16, 18] . Immunostaining of fixed cells can capture protein localization only at a single point in time. Furthermore, permeabilization using common detergents, such as Triton X-100, can destroy membrane-bound organelles such as endosomes, lysosomes, and autophagosomes [19] . As an alternative approach, fluorescently tagged protein reporters have been employed to accurately visualize and track temporal changes of members of the autophagy pathway and proteins destined to this pathway for degradation [16, 18] .
Taking this approach, we developed a live-cell reporter to monitor p16 protein expression in real time. A fluorescent p16-mCherry fusion protein was introduced at the endogenous p16 locus in human retinal pigment epithelial cells (RPE-1) cells using CRISPR-mediated homologous recombination. A p16-mCherry donor cassette for targeted homologous recombination was transfected into RPE-1 cells along with a Cas9 nuclease guided to an untranslated region near the p16 stop codon (Supplemental figure 1A) . mCherry was selected because of its pH stability and ability to maintain fluorescence under acidic conditions, including within the lysosomal lumen [20, 21] . In order to differentiate nuclear from cytoplasmic p16-mCherry and monitor genotoxic stress, we also incorporated a constitutively expressed 53BP1-mVenus reporter in these cells (Supplemental figure 1B) . 53BP1 remains diffusely expressed throughout the nucleus and also localizes to sites of DNA double-stranded breaks [22] . This resulted in the creation of a combined p16-mCherry 53BP1-mVenus reporter cell line (henceforth referred to as RPE p16-mCherry) that could be utilized for subcellular segmentation during live-cell fluorescence experiments (Supplemental figure 1C) .
We first asked how p16 expression and localization changes in response to autophagy and stress. To do this, we treated endogenously-tagged RPE p16-mCherry reporter cells with either DMSO or 20 µM etoposide. Etoposide is a type-II topoisomerase inhibitor that induces DNA double-stranded breaks and activates autophagy [23] . To monitor the activation of autophagy, cells were also treated with Lysotracker, a live-cell chemical stain for V-ATPase activity in acidified vesicles. DMSO-treated control cells exhibited sparse Lysotracker staining, as well as diffuse cytoplasmic and concentrated nuclear p16-mCherry (Figure 2A) . In contrast, etoposide-treated cells displayed bright cytoplasmic puncta in response to Lysotracker, demonstrating that etoposide was sufficient to trigger autophagy. Moreover, these cells accumulated cytoplasmic p16-mCherry puncta that co-localized with Lysotracker, demonstrating that p16-mCherry localizes to acidic cytoplasmic compartments in response to etoposide. Time-lapse images revealed that p16-mCherry puncta began forming approximately 10-12 hours after etoposide treatment ( Figure 2B) .
We next asked how disruption of autophagy affects the expression and subcellular localization dynamics of p16. Autophagy can be inhibited by exposing cells to ammonium chloride (NH4Cl), which raises the luminal pH of intracellular vesicles and prevents the activation of degradative enzymes inside lysosomes [24] . Treatment with 40 mM NH4Cl for 24 hours was sufficient to quench Lysotracker signal in etoposide-treated cells, confirming that vesicular acidification was inhibited by this chemical (data not shown).
RPE p16-mCherry cells were treated with either DMSO or 20 µM etoposide alone, or in combination with 40 mM NH4Cl. We then performed time-lapse fluorescence microscopy for 24 h and compared the ratio of nuclear versus cytoplasmic p16-mCherry. In DMSOonly control cells, p16-mCherry remained nuclear concentrated for 24 h (Figure 2C) . 
Lysosomes recruit p16 during autophagy and attenuate its nuclear localization during genotoxic stress
The autophagy-mediated protein degradation pathway involves the acidification of lysosomes in order to activate low-pH dependent hydrolases within the lysosomal lumen.
Our live-cell experiments revealed co-localization between acidic organelles and p16-mCherry in response to stress. To confirm this finding in a non-reporter cell line, we developed an immunofluorescence protocol suitable for segmenting and quantifying p16 levels in lysosomes within single-cells (Materials and Methods). This protocol was specifically designed to avoid the destruction of membrane-bound organelles, like lysosomes, by permeabilizing fixed cells with digitonin, a selective detergent that punctures the plasma membrane while leaving endomembrane vesicles intact [25] .
Using this modified immunofluorescence technique, we first tested for p16 and lysosome co-localization in unmodified RPE-1 cells undergoing autophagy and genotoxic stress. Control cells treated with DMSO displayed minor visual overlap between p16 and lysosomal-associated membrane protein 1 (LAMP-1) ( Figure 3A) . We then induced concurrent DNA damage and autophagy by treating cells with 20 µM etoposide for 72 h.
Etoposide treatment resulted in easily visible p16 puncta that appeared interspersed among the cytoplasm. These puncta co-localized with LAMP-1, suggesting that a proportion of p16 was recruited to lysosomes upon activation of autophagy. Quantification of total p16 fluorescence intensity revealed that the amount of p16 within lysosomes was significantly increased by etoposide treatment (Figure 3B) . After normalizing for changes in the size and number of lysosomes per cell, the mean p16 intensity per lysosome per cell was also increased after etoposide treatment (Figure 3C ), suggesting active recruitment of p16 to lysosomes during autophagy.
Previous studies have demonstrated considerable cross-talk between subcellular compartments, including between lysosomes and the nucleus [26, 27] . Therefore, we quantified the effects of genotoxic stress and lysosome dysfunction on p16 localization to three subcellular compartments within individual cells: cytoplasm, nucleus, and lysosomes. To do this, we first segmented the nuclei and lysosomes of all cells using chemical and antibody staining of the nucleus (DAPI) and lysosomes (LAMP-1), respectively. Next, using a highly amplified image of p16 antibody staining, we located the exterior borders of each cell and then subtracted the DAPI and LAMP-1 signals to define each cell's cytoplasmic region (Supplemental figure 2A) . We then measured the amount of p16 in each subcellular compartment by dividing the integrated pixel intensity were unchanged. Instead, these cells were found to have significantly higher levels of nuclear p16.
In order to determine if p16 was preferentially targeted to the nucleus in response to lysosomal dysfunction during stress, we created a p16 "localization score" by dividing the mean nuclear, cytoplasmic, or lysosomal p16 fluorescence intensities by the mean p16 intensity of the entire cell (Figure 3E) . This normalization procedure provides a stringent metric of p16 localization by detecting changes in p16 relative to any cell-wide changes in p16 levels, thereby allowing us to determine where the protein was preferentially recruited. Analyzing the p16 localization score in response to each treatment condition revealed that etoposide shifted preferential p16 accumulation to lysosomes and away from the nucleus and cytoplasm. Treatment with NH4Cl attenuated lysosomal localization in response to etoposide and instead shifted p16 accumulation to the nucleus. Furthermore, these cells developed a positive correlation between lysosomal and nuclear p16 localization in response to lysosomal inhibition that was not present in untreated cells (Figure 3F ), suggesting the facilitation of p16 transport between these two subcellular components. In contrast, lysosomal inhibition did not change the correlation between cytoplasmic and nuclear p16 (Supplemental figures 2B) , demonstrating specific interconnectivity between lysosomal and nuclear p16 localization. These results suggest that the combination of genotoxic stress and autophagy triggered by etoposide leads to competition between lysosomal and nuclear p16 enrichment.
Inhibition of autophagy leads to accumulation of p16
The previous experiments showing that p16 localizes with lysosomes led us to ask if the autophagy pathway contributes to p16 degradation. Inhibiting autophagy results in the accumulation of p62 and other proteins destined for lysosomal degradation [21] . Here, we examined the effects of inhibiting autophagy on p16 protein levels using a variety of drugs to probe specific members of the autophagy pathway (Figure 1) . As described previously, ammonium chloride prevents lysosomal degradation by raising luminal pH.
Degradation can also be perturbed through direct inhibition of lysosome-associating vesicles. For example, bafilomycin A1 and chloroquine are potent inhibitors of late stage autophagy that act by preventing fusion between autophagosomes and lysosomes [28] ; [29] .
RPE-1 cells were treated with autophagy/lysosome inhibitors bafilomycin A1 (BAFA1, 100 nM), chloroquine (CHQ, 20 µM), and ammonium chloride (NH4Cl, 40 mM), or the proteasome inhibitor MG132 (0.5 µM) for 24 h. Immunoblotting of whole cell lysates revealed increased p16 protein levels with either lysosome or proteasome inhibitors (Figures 4A and 4B ). p62 levels also increased with every autophagy inhibitor, confirming dysregulation of the autophagosome-lysosome pathway. To determine if inhibition of autophagy promoted senescence, we also stained for phosphorylated-Rb on serine 780, a site specifically targeted by cyclin D1-CDK4 when the cell cycle is active [30] . Every autophagy inhibitor tested resulted in significantly lower phosphorylated-Rb (S780). RT-qPCR revealed that increases in p16 protein in response to autophagy inhibition were not the result of de novo p16 transcription (Figure 4C) . Together these results demonstrate that p16 can be degraded by the autophagy/lysosomal pathway and implicate autophagy as a potential regulator of cell cycle progression.
p16 is targeted to autophagosomes by p62/SQSTM1
Proteins destined for lysosomal degradation are first targeted to autophagosomes and endosomes produced by the endomembrane system. We therefore asked if p16 is targeted to autophagosomes. Immunofluorescence revealed that autophagy inhibitor chloroquine perturbed the clearance of autophagosomes, resulting in stalled and enlarged cytoplasmic vacuoles containing autophagosome marker LC3 (Supplemental figure 3A) . To determine if p16 is targeted to autophagosomes, we treated RPE-1 cells with DMSO or 20 μM chloroquine for 24 hours. Immunofluorescence revealed that DMSO-treated cells stained positive for diffuse cytoplasmic p16 and concentrated nuclear p16 (Figure 4A and 4B) . In these cells, the autophagosome marker LC3 and chaperone p62 were either sparse or undetectable, a phenomenon known to be caused by rapid autophagic flux [18] . Disruption of autophagy via chloroquine treatment caused aggregation of cytoplasmic p16 puncta, which co-localized with LC3-and p62-positive puncta, indicating that p16 is targeted to autophagosomes (Figure 4A and 4C) . Silencing of p62 via siRNA knockdown ablated p62 puncta and resulted in fewer cytoplasmic p16 aggregates forming in response to chloroquine treatment. LC3 puncta formation was unaffected by p62 knockdown. Additionally, knockdown of p62 combined with chloroquine resulted in delocalization of p16 puncta from LC3, indicating that p62 is responsible for the aggregation of p16 and its localization to autophagosomes. In contrast, siRNA knockdown of p16 eliminated p16 puncta without disrupting LC3 and p62 expression and co-localization, demonstrating that p16 is not necessary for autophagosome formation (Supplemental figures 3B and 3C) . The dependence of p16 aggregation on p62 was further suggested by immunofluorescence staining of chloroquine-treated cells, which revealed a significant correlation between p62 and p16 fluorescence intensity co-localized within LC3 puncta (Figure 4D) . Taken together, these results demonstrate that autophagy triggers localization of p16 to autophagosomes in a manner that is dependent on the expression of the chaperone p62.
Discussion
In summary, our study demonstrates that localization and degradation of the p16 protein is regulated in part by the autophagy-lysosomal pathway. Lysosomal p16 enrichment occurs in response to DNA damage and autophagy induced by the chemotherapeutic agent etoposide. However, genotoxic stress in the presence of lysosome dysfunction leads to preferential nuclear accumulation of p16. Inhibiting autophagy raises p16 protein levels within 24 h without stimulating de novo p16 gene expression, demonstrating that p16 can be degraded by this pathway. Additionally, we found that recruitment of p16 to autophagosomes requires the chaperone protein p62.
Together, these results reveal an unappreciated mode of regulation of the p16 protein in human cells.
Traditionally, protein localization has been studied with immunohistological experiments using antibodies targeting the protein of interest. However, these methods require the fixation of cells, which prevents temporal analysis of protein expression and localization. The autophagy pathway and endomembrane system is dynamic, mobile, and known to induce drastic changes in protein localization in a relatively short time-frame.
By creating an endogenous p16-mCherry reporter in human cells, we have contributed a novel tool for examining p16 expression and translocation over time. Utilization of this reporter in future experiments will help to further our understanding of p16 dynamics in response to chemotherapeutic agents, cellular stress, and autophagy dysfunction.
Further study is required to identify the precise mechanisms that control p16 localization. For example, it is not known which domains on the p16 protein are responsible for autophagosomal and lysosomal recruitment. While we have found that p62 is required for p16 recruitment to autophagosomes, the endomembrane-transport system is complex, with many additional chaperone proteins and post-translational modifiers involved in recruiting, sorting, and shuttling cargo between different compartments of the cell. Determining the specific factors that control p16 transport could reveal potential drug targets for disease and anti-aging therapies.
We found that inhibiting autophagy led to p16 accumulation, decreased phosphorylated-Rb, and perturbed cell growth. Furthermore, the general lack of p16 aggregates under basal conditions implies that, in the cell lines tested, p16 remains in autophagic flux, which may allow replicating cells to sustain basal levels of p16 expression without inducing cell-cycle arrest. Additionally, we have demonstrated that activation of autophagy recruits p16 to lysosomes for degradation, which may prevent p16-induced senescence despite increases in p16 expression stimulated by cellular stress. It is intriguing, therefore, that inhibiting lysosomal degradation leads to nuclear accumulation of p16. Previous studies have shown that there is considerable cross-talk between lysosome-to-nuclear signaling and stress response proteins, including mTOR [27] . Our study expands this relationship to the tumor suppressor p16, and links p16 localization to lysosomal function, which both serve as key regulators of senescence, disease, and aging.
Since the p16 protein has long been known to promote cell cycle arrest through inhibition of CDK4/6 in the nucleus, these results suggest-but do not prove-a potential competition between the autophagy and senescence pathways through the sequestration of p16 (Figure 5A) . Under this hypothetical model, stress induces the slow production of p16, which is quickly recruited to autophagosomes and degraded by lysosomes via the autophagy pathway. Over time, either through enhanced transcriptional activity or through p16 protein localization outside of lysosomes, p16 is able to enter the nucleus to bind to CDK4/6 and arrest the cell cycle. However, if the autophagy pathway is inhibited, p16 preferentially accumulates in the nucleus, which could lead to premature senescence ( Figure 5B ). From this model, we posit that autophagy "buys time" for cells undergoing stress to determine whether the damage is manageable and cells are able to resume proliferation once the stress conditions are eliminated. Alternatively, if stress conditions persist, or if autophagy is dysregulated, the cell enters senescence. Future studies will be necessary to determine whether sequestration of p16 through the autophagy-lysosomal pathways reduces a cell's tendency to undergo senescence.
Finally, the observation that p16 localizes to and is degraded by lysosomes represents a potentially novel thread of research for cancer cell biology. Commonly used chemotherapeutic drugs can induce increases in p16 expression in patients, but the effect of these agents on p16 localization in single cells has not been fully explored.
Understanding how these compounds effect p16 localization could illuminate our understanding of how these treatments work at a mechanistic level. The ability to control senescence and attenuate cell growth via combined treatment with chemotherapeutics and well-established autophagy inhibitors could have major implications in the treatment of tumor progression. Beyond this application, the ability to slow or prevent senescence in healthy proliferating cells, such as stem cells, could lead to potential new therapies for other age-related diseases. In addition, we believe it is worth exploring the role of p16 in lysosomal storage diseases, which account for dozens of disorders associated with the brain, skin, heart, and central nervous system. ice cold PBS and fixed with 4% PFA for 10 minutes at room temperature. Cells were permeabilized and blocked with 0.02% digitonin (Invitrogen BN2006) in PBS containing 5% serum for one hour at room temperature. All following steps were performed in wash buffer containing 5% serum in PBS. First, cells were incubated overnight at 4°C in wash buffer containing Anti-CDKN2A/p16INK4a antibody (Abcam ab108349), Anti-LAMP1 antibody (Abcam ab25630), Anti-SQSTM1/p62 antibody (Abcam ab56416), or Anti-LC3B antibody (Abcam ab192890). The following day, cells were washed three times for five minutes with wash buffer. Cells were then incubated for one hour at room temperature in wash buffer containing mouse and rabbit conjugated secondary antibodies. For p62 and LC3 staining experiments, cells were then washed three times for five minutes with PBS, blocked again for one hour in wash buffer, and then incubated overnight at 4°C in wash buffer containing Anti-CDKN2A/p16INK4a conjugated (Alexa Fluor 647) antibody (Abcam ab192054). Cells were then washed with PBS containing 1 µg/mL DAPI for five minutes at room temperature, followed by three five-minute washes with PBS before visualization.
Materials and Methods
Cell culturing and maintenance
Autophagy inhibitors
Segmentation, counting, and fluorescence quantification of cells, subcellular compartments, and fluorescent puncta were performed in CellProfiler. Puncta clustering analysis was performed in CellProfiler using the adjusted Rand index measured between fluorescent channels. Measured results were plotted and tested for statistical significance in MATLAB using ANOVA and Bonferroni correction for multiple comparison analysis. 
Western blot and protein quantification
